Alexandria Real Estate Equities Inc.

ARE ·Real Estate, REIT - Diversified, United States

Alexandria Real Estate Equities, Inc. (ARE)

Overview

Alexandria Real Estate Equities is a real estate investment trust (REIT) headquartered in Pasadena, California, that pioneered and remains the preeminent owner, operator and developer of life-science real estate — laboratory and office buildings leased to biotechnology, pharmaceutical and life-science technology tenants. Founded in 1994 and taken public in 1997, Alexandria organizes its properties into "megacampus" clusters concentrated in the country's top life-science innovation hubs: Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. The company owned or held interests in several hundred properties totaling more than 40 million square feet as of recent filings, employs roughly 500 people, and generated trailing twelve-month revenue of about $2.8 billion. Alexandria has faced a difficult stretch since 2023-2025, however, as a post-pandemic glut of new lab space and a slowdown in biotech funding pushed occupancy down, forced large real estate impairments, and led the company to cut its dividend sharply in late 2025.

What They Do & How They Make Money

As a REIT, Alexandria's core business is owning income-producing real estate and collecting rent, but its specialization is narrow and deliberate: rather than generic office or industrial space, it develops and leases highly specialized "labspace" — buildings engineered with the ventilation, power, plumbing and structural specifications that wet-lab science requires — to life-science companies ranging from early-stage biotech startups to the world's largest pharmaceutical and biotech firms. Revenue comes primarily from long-term leases (often 10+ years for larger anchor tenants) with contractual rent escalations, supplemented by fees from development and redevelopment projects the company undertakes on its own land and by returns from Alexandria Venture Investments, an in-house venture capital arm that takes equity stakes in early-stage life-science companies — many of which become future tenants, creating a symbiotic pipeline between Alexandria's capital and its real estate leasing business. Because life-science tenants cluster deliberately near research universities, major hospital systems, and each other (to share talent and collaborate), Alexandria's strategy of building large, amenity-rich "megacampuses" in a handful of proven innovation hubs — rather than spreading properties broadly — is central to its pricing power and tenant retention. The company also periodically recycles capital by selling stabilized or non-core assets and redeploying proceeds into new development projects with higher expected returns.

Business Segments

Unlike diversified industrial companies, Alexandria does not report multiple product-line business segments; as a REIT it is functionally organized as a single life-science real estate operating platform, with performance instead broken out by geographic cluster/submarket and by operating stage of its assets:

Operating properties — stabilized, leased laboratory and office buildings generating the bulk of rental revenue.
Development and redevelopment pipeline — properties under construction or being repositioned for future lease-up, representing near-term growth (and, in the current environment, financial risk, since new supply must find tenants).
Regional clusters — Greater Boston and the San Francisco Bay Area are historically the two largest revenue contributors, followed by San Diego, Seattle/Maryland, Research Triangle, and New York City.
Alexandria Venture Investments — a smaller but strategically important venture capital portfolio in life-science companies, generating investment gains/losses that flow through non-operating income and support the tenant pipeline.

Recent results reflect significant stress across this platform: Alexandria recorded roughly $1.7 billion in real estate impairment charges around Q4 2025 as it wrote down the value of underperforming assets, and full-year revenue trends turned negative (management has guided to modestly declining revenue over the near term) as elevated vacancy and softer leasing demand outweighed contractual rent growth on existing leases.

Competitors

Healthpeak Properties — a diversified healthcare REIT with a meaningful life-science portfolio, one of Alexandria's closest public-market peers in lab real estate.
BXP (formerly Boston Properties) — a large office REIT that has expanded into life-science lab development in markets like Cambridge/Boston, competing directly with Alexandria for anchor biotech and pharma tenants.
Kilroy Realty Corporation — an office and life-science REIT with a significant life-science development presence in markets such as South San Francisco (e.g., the Oyster Point campus).
BioMed Realty — a large private life-science real estate owner (owned by Blackstone) that competes directly with Alexandria in core life-science submarkets.
IQHQ — a private, well-capitalized life-science real estate developer that has aggressively built new lab space in several of Alexandria's core clusters (San Francisco, San Diego, Boston), contributing meaningfully to the recent oversupply.
More broadly, Alexandria competes with regional developers and other diversified office/industrial landlords converting space into lab use, as well as with universities' and hospital systems' own real estate arms in some submarkets.

Competitive Position

Alexandria's moat has historically rested on being the first-mover and largest scaled operator in life-science real estate, with irreplaceable "megacampus" land positions in the most tenant-desirable innovation clusters, deep relationships with the biotech and pharmaceutical industry's top companies, and specialized in-house development and lab-engineering expertise that generalist REITs cannot easily replicate. Its Alexandria Venture Investments arm gives it a differentiated pipeline into future tenants that competitors lack, and long lease terms with high-quality, often investment-grade pharmaceutical tenants have historically provided very stable, growing cash flow.

That moat has been severely tested since 2023. A surge of new lab-space construction — much of it delivered by well-capitalized private developers like IQHQ and by public peers converting office assets — created a substantial oversupply just as biotech venture funding cooled from its 2020-2021 boom and many tenants pulled back on real estate footprints or went out of business. The result has been rising vacancy, weaker leasing spreads, and roughly $1.7 billion of real estate impairments recorded around the end of 2025, which — combined with debt levels not fully covered by operating cash flow — forced Alexandria to cut its dividend by approximately 45% in December 2025 to preserve liquidity, alongside a $500 million share buyback authorization and new debt issuance (including $1 billion of subordinated notes in August 2026) to shore up its balance sheet. Management continues to point to a differentiated portfolio (evidenced by continued high-profile deliveries, such as an R&D hub for Bristol Myers Squibb in San Diego) as a reason it should outlast weaker competitors and out-navigate the current down-cycle, but near-term risk remains centered on how quickly biotech funding recovers, how much further vacancy rises before oversupply is absorbed, and the company's ability to service debt while revenue is guided to decline over the next few years.